Juliette Berangere Audet Acquires 1,104 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma (NASDAQ:NAMS) insider Juliette Berangere Audet acquired 1,104 shares of the company’s stock in a transaction dated Thursday, September 26th. The stock was acquired at an average cost of $15.70 per share, for a total transaction of $17,332.80. Following the completion of the acquisition, the insider now directly owns 1,104 shares in the company, valued at $17,332.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

NewAmsterdam Pharma Stock Up 4.2 %

NAMS opened at $17.29 on Wednesday. The firm’s fifty day simple moving average is $16.50 and its two-hundred day simple moving average is $18.92. NewAmsterdam Pharma has a 52-week low of $5.63 and a 52-week high of $26.35.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Wednesday, August 7th. The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.08. The business had revenue of $2.28 million during the quarter, compared to analyst estimates of $2.20 million. Equities research analysts expect that NewAmsterdam Pharma will post -2.06 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on NAMS shares. Needham & Company LLC assumed coverage on shares of NewAmsterdam Pharma in a report on Wednesday, August 28th. They issued a “buy” rating and a $36.00 price objective on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $31.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Finally, Piper Sandler reissued an “overweight” rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $33.80.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of hedge funds have recently modified their holdings of NAMS. Jennison Associates LLC acquired a new stake in NewAmsterdam Pharma during the first quarter worth about $22,015,000. Artal Group S.A. acquired a new stake in NewAmsterdam Pharma during the first quarter worth about $18,920,000. Janus Henderson Group PLC acquired a new stake in NewAmsterdam Pharma during the first quarter worth about $15,018,000. Decheng Capital LLC acquired a new stake in NewAmsterdam Pharma during the second quarter worth about $7,684,000. Finally, Opaleye Management Inc. purchased a new position in NewAmsterdam Pharma during the fourth quarter worth about $2,964,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.